Integrated BioPharma, Inc. reported a significant YoY revenue decrease of 19.3% for the fiscal year ended June 30, 2026, primarily driven by reliance on high-concentration customers in its Contract Manufacturing Segment.
Integrated BioPharma, Inc. reported a significant YoY revenue decrease of 19.3% for the fiscal year ended June 30, 2026, primarily driven by reliance on high-concentration customers in its Contract Manufacturing Segment.